POS0748 TOWARD THE DEFINITION OF CUTOFF VALUES FOR DISEASE ACTIVITY STATES IN SYSTEMIC JADAS
Authors: A. I. Rebollo Giménez, Y. Vyzhga, L. Carlini, S. Rosina, E. Patrone, M. Katsikas, C. Saad-Magalhaes, D. El-Ghoneimy, Y. El Miedany, R. Khubchandani, P. Pal, G. Simonini, G. Filocamo, M. Gattinara, F. De Benedetti, D. Montin, A. Civino, M. O. Alsuweiti, V. Stanevicha, V. Chasnyk, E. Alexeeva, S. Al-Mayouf, S. Vilaiyuk, A. Ravelli
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Systemic juvenile idiopathic arthritis (sJIA) accounts up to 15 % of all patients with JIA and is distinct from the other disease categories due to the association of articular and extraarticular manifestations. The systemic Juvenile Arthritis Disease Activity Score (sJADAS) is a composite disease activity score validated specifically for use in sJIA that includes, beside the four components of the original JADAS, a fifth item aimed to quantify the burden of systemic features. The interpretation of scores on sJADAS requires criteria that identify the states of disease activity. These criteria can be used to monitor the disease course over time and to define therapeutic targets. <h3>Objectives</h3> To compare the clinical and laboratory data of each disease activity state in patients enrolled in the multinational study aimed to define the sJADAS cutoffs. <h3>Methods</h3> Data were extracted from a multinational cross-sectional dataset that included patients diagnosed as sJIA by ILAR criteria, recruited between February 2022 and November 2022. At study visit, each patient was categorized subjectively by the caring physician into one of the following disease activity states: inactive disease (ID), low (or minimal) disease activity (LDA), moderate disease activity (MDA), or high disease activity (HDA). Study data was collected through a standard case report form and entered into an electronic database. <h3>Results</h3> A total of 231 patients were enrolled in 29 centers in 12 countries. The mean age at diagnosis was 5.63 years. 87 patients (37.7%) were judged as having ID, 39 (16.9%) LDA, 46 (19.9%) MDA and 59 (25.5%) HDA. The comparison of the main clinical and laboratory features across patients with the four disease activity states is shown in the Table 1. Overall, the presence of extraarticular manifestations was more common in patients with MDA and HDA (P&lt;0.00001), whereas fever, rash, hepatosplenomegaly, and lymphadenopathy were more frequent in HDA patients (&lt;0.00001). The count of active joints increased progressively from ID to HDA (p&lt;0.00001). The mean values of physician global assessment of disease activity and systemic manifestations, as well as the mean values of acute phase reactants, were highest in patients with HDA, with gradual decrease from MDA to LDA to ID. <h3>Conclusion</h3> This preliminary analysis of the study data indicates that the subjective assessment of disease state by the caring physicians led to discriminate reliably patients with different level of disease activity. This evaluation will, then, serve well as reference for the subsequent analyses aimed to identify the cutoffs for the main disease activity states in sJIA. <h3>Reference</h3> [1]Tibaldi J, Pistorio A, Aldera E, et al. Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology (Oxford). 2020 Nov 1;59(11):3505-3514. <h3>Acknowledgements</h3> This work was partially supported by the Fundación Española de Reumatología (FER). <h3>Disclosure of Interests</h3> Ana Isabel Rebollo Giménez: None declared, Yulia Vyzhga: None declared, Luca Carlini: None declared, Silvia Rosina: None declared, Elisa Patrone: None declared, Maria Katsikas: None declared, Claudia Saad-Magalhaes: None declared, Dalia El-Ghoneimy: None declared, Yasser El Miedany: None declared, Raju Khubchandani: None declared, Priyankar Pal: None declared, Gabriele Simonini Grant/research support from: educational grants from Abbvie, Sobi, Novartis, Giovanni Filocamo Consultant of: consultancies from Sobi and Novartis, Maurizio Gattinara: None declared, Fabrizio De Benedetti: None declared, Davide Montin: None declared, Adele Civino: None declared, Motasem O. Alsuweiti: None declared, Valda Stanevicha: None declared, Vyacheslav Chasnyk: None declared, Ekaterina Alexeeva Speakers bureau: speakers bureaus for Roche, Novartis and Pfizer., Grant/research support from: research grants from Roche, Pfizer, Centocor, Eli Lilly, AbbVie, Bristol-Myers Squibb, MSD, Sanofi, Amgen and Novartis., SULAIMAN AL-MAYOUF Speakers bureau: speaker fees from Sobi and Novartis, Soamarat Vilaiyuk: None declared, Angelo Ravelli Speakers bureau: from:Abbvie, Angelini, Pfizer, Novartis, BMS, Reckitt Benckiser, Sobi, Alexion, Roche.